Home/News/June 2021/CG01-GMP plasmids released - Ready to start GMP production of CG01
CG01-GMP plasmids released - Ready to start GMP production of CG01
Cobra Biologics (Cobra), the gene therapy division of Cognate BioServices, a Charles River Laboratories International, Inc. company and CombiGene AB (publ) (CombiGene), the leading gene therapy company in the Nordic region, today announce that they have successfully completed the production and quality assurance of the plasmids to be used in the GMP production of CG01, for CombiGene's gene therapy for the treatment of drug-resistant focal epilepsy.
Mike Austin, Corporate Vice President, Global Operations Cell and Gene Therapy CDMO, Charles River, comments: “We are pleased to continue the journey with CombiGene and the release of the GMP plasmids represents a crucial step in the production of CG01. We have a well-established plasmid production platform and in-house expertise in quality control that will ensure the delivery of GMP quality plasmid.”